Research team

Expertise

My research is focused on studying human and animal pathogens and their commensal microbial flora in the context of infectious diseases by utilizing molecular microbiology and bioinformatics. My main effort is dedicated to study: (1) The impact of broad-spectrum antibiotic treatment on the human commensal flora and how antiseptics can be utilized to prevent colonization with antibiotic-resistant pathogenic bacteria. Specifically, by utilizing 16S rRNA gene and shotgun metagenomic sequencing technologies, the antibiotic impact on microbial composition, metabolic activity, and antibiotic resistance mechanisms harbored within the host microbial flora is studied in relation to development of adverse events like antibiotic-associated diarrhea (AAD) and Clostridioides difficile infection (CDI). Further, I study acquisition and transmission of resistant organisms within neonatal intensive care units in Europe and how decontaminating measures can be utilized for prevention. (2) Mechanisms of antibiotic resistance and virulence in pathogenic bacteria. Both clinical, patient-derived as well as in vitro-passaged bacterial strains, namely Clostridioides difficile and Pseudomonas aeruginosa, are studied using strain typing and whole genome sequencing to determine resistance stability and fitness cost to understand emergence of the resistance mechanisms as well as their fate in the community. (3) Markers within the respiratory microflora and genetic features of the SARS-CoV-2 virus predictive of disease severity and infection within the framework of a large pan-European COVID-19 cohort study including a large number of patient samples derived from health-care workers, fragile populations, severely ill COVID-19 patients, and healthy populations.

One HeAlth InteRventIon and TransmiSSion in AMR (HARISSA). 01/02/2022 - 31/01/2026

Abstract

The project, Microbiota Intervention Strategies Limiting Selection and Transmission of Antibiotic Resistance burden in the One Health domain (MISTAR, https://www.jpiamr.eu/projects/mistar/) aims to bring perspectives on novel interventions to reduce the emergence of antibiotic resistance that can readily be integrated into existing organisational structures that are also applicable in low-and-middle income countries, and innovative technologies, which need further investment. MISTAR aims to implement and quantify the effect of novel intervention strategies based on the preservation of the "healthy microbiota" to eradicate and control the spread of antimicrobial resistance (AMR). ¶¶Òõ¶ÌÊÓÆµ laboratories are studying resistomes in a global context, using a One Health approach, and aims to (1) Predict and prevent antibiotic-induced microbial dysbiosis in the gut and post-antibiotic resistome response, (2) Develop microbiota-based rapid point of care diagnostic pipelines for AMR detection, (3) Determine the efficacy of CRISPR-Cas target intervention on resistome across reservoirs. The project is funded by Joint Programming Initiative in Antimicrobial Resistance (JPIAMR, 13th call, 2021) and FWO.

Researcher(s)

Research team(s)

Project type(s)

  • Research Project